Four months have passed since Evestia Clinical and Atlantic Research Group (ARG) came together to form a united, independent global specialist CRO. In this Q&A, Lewis Cameron, CEO of Evestia Clinical, reflects on what the integration has achieved, what it means for our partners, and how it has accelerated the company’s long-term strategy.
1: Four months in, what stands out most about the merger’s impact?
What stands out is how quickly our combined strengths have already delivered meaningful value for our biotech partners. The merger has expanded our global footprint across the US, UK and Europe while deepening our expertise in neurology and extending our late-stage clinical trial capabilities.
The merger has enabled us to stay firmly anchored in the therapeutic areas where we add the most value, while enhancing our ability to support complex, multi-region trials with precision and care.
Looking back, this step has reinforced our commitment to intentional, specialist growth rather than broad, unfocused expansion.
2: How has the merger influenced the client experience and the way teams work together?
Our fully integrated global teams now collaborate across enlarged geographies and complementary therapeutic areas, giving innovators direct access to a broader set of capabilities without losing the personalized support they expect from Evestia Clinical.
The cultural alignment between Evestia Clinical and ARG, especially around partnership, agility, and care, has been a major driver of smooth integration. Partners now benefit from unified global operations, increased leadership visibility, and expanded capabilities that better support Phase 1, 2 and 3 programs.
The transition has been seamless for ARG’s clients, who immediately gained access to Evestia Clinical’s global presence, advanced technologies, and new therapeutic strengths, including rare disease.
3: In what ways has the merger strengthened Evestia Clinical’s support for small and mid-sized biotechs?
Our biotech-focused model remains at the heart of how we operate. Biotechs value flexibility, transparency, and direct access to senior decision-makers, and the merger enables us to preserve all three.
We now offer enhanced therapeutic depth, expanded service lines spanning Phases 1–3 and beyond, and a broader global delivery model. Yet we remain intentionally specialist and accessible.
By combining ARG’s world-class neurology expertise and established US footprint with Evestia Clinical’s strengths in oncology, rare disease, immunology, and advanced therapies, we now support innovators with the scale they need and the agility they expect. Their science deserves nothing less.
4: What unique strengths did each organization bring, and how do they now complement each other?
Evestia Clinical brought deep expertise in oncology, rare disease, immunology, and inflammation, a growing global platform, and a strong track record of operational excellence. ARG contributed world-class neurology capability, especially in neuromuscular disease such as ALS, Huntington’s disease, and Parkinson’s disease, alongside a long-standing US presence and proven late-stage trial experience.
The enlarged organization now delivers a comprehensive and highly specialized global service offering across the key therapeutic areas where biotechs most need support, like oncology and complex neuromuscular disease.
Importantly, ARG’s CEO and President have joined our senior leadership team, strengthening our global operational capability and ensuring continuity for clients.
5: How has the combined capability improved client relationships and long-term partnerships?
Many of our partners have worked with us for years. The merger has enhanced these relationships by giving them continuity of leadership, expanded service options, and broader global delivery.
Partners can now work with one CRO across all major phases of development. This consistency, combined with shared scientific understanding and an expanded team, has deepened trust, strengthened collaboration, and enabled innovators to plan with greater confidence.
The enlarged group’s integrated technology platform further supports smoother and more connected trial execution.
6: What is your vision for the organization now that the integration is well underway?
Our vision remains one of controlled, strategic growth. We are building the leading global mid-tier specialist CRO, expanding our services, deepening our therapeutic focus, and broadening our global footprint, all while preserving the agility and senior-level access that define us.
The past four months have shown that this strategy works. We continue to grow with purpose, guided by our EPIC values of Excellence, Partnership, Innovation, and Care.
7: If you could leave biotech innovators with one message about what this merger represents, what would it be?
This merger represents access to an experienced leadership team, global specialist CRO expertise, and a partner deeply committed to supporting biotech innovators on every step of the drug development journey.
Our objective is simple: to provide a personalized, science-aligned, white-glove service that helps transform complex clinical programs into successful milestones. Your science deserves nothing less.
Looking ahead
Four months on, the merger has validated our strategy: focused therapeutic depth, global scale, expanded technology, and dedicated biotech-centric service. We look forward to continuing this journey with our partners as we grow our capabilities and support innovators as they bring life-changing therapies to patients worldwide.
Reach out to the Evestia Clinical team to learn more about how our expanded capabilities can support you in your next trial: info@evestiaclinical.com
Partner With Us
When every decision matters, we make sure you get it right.
